[siteorigin_widget class=”SiteOrigin_Widget_Headline_Widget”][/siteorigin_widget]
[siteorigin_widget class=”SiteOrigin_Widget_Headline_Widget”][/siteorigin_widget]
The endocannabinoid system (ECS) is a widespread neuromodulatory system that plays an important role in human central nervous system development, synaptic plasticity, and the response to endogenous and environmental insults.

Numerous peer reviewed, scientific publications have shown its importance in human physiology as a modulator of cardiovascular, gastrointestinal, and immune function, metastatic transformation and key aspects of central nervous system function, including movement disorders, pain, and behavior. The ECS is therefore an attractive and validated target for pharmacological intervention.

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]
[siteorigin_widget class=”TTrust_Spacer”][/siteorigin_widget]
[siteorigin_widget class=”SiteOrigin_Widget_Headline_Widget”][/siteorigin_widget]

Artelo’s business model is to develop multiple pharmacological approaches to ECS modulation. Candidate therapeutic compounds within our current portfolio are based on targeting cannabinoid receptors and endocannabinoid transport inhibition.

Modulating the ECS shows vast promise to relieve an array of symptoms, including pain, nausea, anxiety, sleeplessness, decreased appetite, and inflammation. The clinical use of cannabinoids is probably best known in multiple sclerosis and nausea associated with cancer, and there are several pharmaceutical products that modulate the ECS already available in many countries.

Artelo Biosciences is developing a diverse portfolio of product candidates targeting the endocannabinoid system

View our pipeline >